Paper · 36545708
Cited by131
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 166 citations.
1 to 20 of 131
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42967027 | Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42967027 | PubMed |
| 42958661 | Xiaoyao San enhances the sensitivity of hepatocellular carcinoma to 5-fluorouracilautophagy modulation. | J Tradit Chin Med | 2026 | https://conductscience.org/library/papers/42958661 | PubMed |
| 42927357 | Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/42927357 | PubMed |
| 42893081 | Construction of a Nomogram Integrating Magnetic Resonance Imaging Features and Ephrin-A3 Expression to Predict Postoperative Overall Survival in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42893081 | PubMed |
| 42724514 | Akkermansia muciniphila attenuates apatinib resistance in hepatocellular carcinoma through NF-κB-mediated reprogramming of tumor-associated macrophages. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724514 | PubMed |
| 42592511 | A gradient core-shell microsphere to enable effective embolization of liver cancer via interventional therapy. | Regen Biomater | 2026 | https://conductscience.org/library/papers/42592511 | PubMed |
| 42588737 | The Controlling Nutritional Status Score as a Predictive Factor for Lung Metastasis in Patients with Hepatocellular Carcinoma After Hepatectomy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588737 | PubMed |
| 42564342 | Prediction of early treatment response to drug-eluting beads chemoembolization for hepatocellular carcinoma using machine learning. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42564342 | PubMed |
| 42542804 | HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42542804 | PubMed |
| 42540626 | Apatinib resistance mediated by IRF9 nuclear translocation in head and neck squamous cell carcinoma. | iScience | 2026 | https://conductscience.org/library/papers/42540626 | PubMed |
| 42445440 | The evolving landscape of early diagnosis for hepatocellular carcinoma: a bibliometric analysis of global research trends (2016-2026) based on WoSCC database. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42445440 | PubMed |
| 42440203 | Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression. | Saudi Pharm J | 2026 | https://conductscience.org/library/papers/42440203 | PubMed |
| 42433265 | Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study. | Liver Cancer | 2026 | https://conductscience.org/library/papers/42433265 | PubMed |
| 42373443 | [Transitional and clinical practice pathways for whole-course management of hepatocellular carcinoma in the infectious diseases department]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42373443 | PubMed |
| 42358545 | AAT score based on pretreatment indicators predicts outcomes in unresectable HCC patients treated with TACE, Sintilimab, and Bevacizumab. | Front Oncol | 2026 | https://conductscience.org/library/papers/42358545 | PubMed |
| 42326932 | Cost-effectiveness analysis of Atezolizumab plus bevacizumab vs. Rivoceranib plus Camrelizumab as first-line treatment for unresectable hepatocellular carcinoma. | Front Public Health | 2026 | https://conductscience.org/library/papers/42326932 | PubMed |
| 42304258 | MRI radiomics and 90Y PET dosimetry for predicting hepatocellular carcinoma response after radioembolization. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42304258 | PubMed |
| 42301580 | TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis. | Eur Radiol Exp | 2026 | https://conductscience.org/library/papers/42301580 | PubMed |
| 42292386 | Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292386 | PubMed |
| 42270819 | Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study. | Sci Rep | 2026 | https://conductscience.org/library/papers/42270819 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/36545708/cited_by